Guggenheim analyst Louise Chen said her sum-of-the-parts analysis suggests that Endo could be worth $30-$51 per share, adding that she believes the company could drive its stock price up by 50% or more if it were to sell its brand business and non-core international assets and focus on generics. If it were to opt for that route, Endo "may do better as a private company," given the lack of visibility into Par's generic pipeline and Wall Street's focus on drug pricing, added Chen. The firm has a Buy rating and $35 price target on Endo shares, which are up 1.8% to $20.16 near midday.